Benign prostatic hyperplasia and subsequent risk of bladder cancer

被引:0
作者
D Kang
A P Chokkalingam
G Gridley
O Nyren
J E Johansson
H O Adami
D Silverman
A W Hsing
机构
[1] National Cancer Institute,Division of Cancer Epidemiology and Genetics
[2] College of Medicine,Department of Medical Epidemiology and Biostatistics
[3] Seoul National University,Department of Urology and Clinical Medicine and Center for Assessment of Medical Technology
[4] School of Public Health,undefined
[5] University of California,undefined
[6] Karolinska Institute,undefined
[7] Obrebro University Hospital,undefined
来源
British Journal of Cancer | 2007年 / 96卷
关键词
benign prostatic hyperplasia; prostate cancer; population-based; standardised incidence ratio;
D O I
暂无
中图分类号
学科分类号
摘要
We evaluated the risk of bladder cancer in a cohort of 79 280 Swedish men hospitalised for benign prostatic hyperplasia (BPH), identified in the Swedish Inpatient Register between 1964 and 1983 and followed until 1989 via multiple record linkages with nationwide data on cancer registry, death and emigration. Standardised incidence ratios (SIRs), the ratios of the observed to the expected numbers of incident bladder cancers, were used to calculate the risk associated with BPH. The expected number was calculated by multiplying the number of person-years by the age-specific cancer incidence rates in Sweden for each 5-year age group and calendar year of observation. Analyses were stratified by BPH treatment, latency, calendar year and presence of genitourinary (GU) comorbid conditions. After excluding the first 3 years of follow-up after the index hospitalisation, we observed 506 incident bladder cancer cases during follow-up in the cohort. No overall increased risk of bladder cancer was apparent in our main analysis involving the entire BPH cohort. However, among BPH patients with transurethral resection of the prostate (TURP), there was an increased risk in all follow-up periods; SIRs of bladder cancer during years 4–6 of follow-up was 1.22 (95% confidence interval=1.02–1.46), 1.32 for 7–9 years of follow-up, and 1.47 for 10–26 years of follow-up. SIRs of bladder cancer among TURP-treated BPH patients were particularly elevated among those with comorbid conditions of the GU tract (e.g., stone, infection, etc.); 1.72, 1.74 and 2.01 for 4–6, 7–9, 10–26 years of follow-up, respectively, and also for those whose diagnoses occurred before 1975, when TURP was more likely to be performed by a urologist than a general practitioner: 1.87, 1.90 and 1.74, respectively. These findings suggest that BPH overall is not associated with bladder cancer risk. However, among men treated with TURP, particularly those with other comorbid GU tract conditions, risk of bladder cancer was elevated.
引用
收藏
页码:1475 / 1479
页数:4
相关论文
共 80 条
[1]  
Bailar JC(1964)Significance factors for ratio of a Poisson variable to its expectation Biometrics 20 639-643
[2]  
Ederer F(1997)Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs Urology 50 214-219
[3]  
Blomqvist P(2001)Impact of medical therapy on transurethral resection of the prostate: a decade of change Urology 57 1082-1085
[4]  
Ekbom A(1987)Statistical methods in cancer research. Volume II – The design and analysis of cohort studies IARC Sci Publ 82 1-406
[5]  
Carlsson P(2003)Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden Cancer 98 1727-1734
[6]  
Ahlstrand C(1997)Risk of urinary tract cancers following kidney or ureter stones J Natl Cancer Inst 89 1453-1457
[7]  
Johansson JE(2002)The urologist view of BPH progression: results of an international survey Eur Urol 41 490-496
[8]  
Borth CS(1993)Video TUR: raising the gold standard. New aspects, techniques and tendencies to minimize invasiveness Eur Urol 24 256-261
[9]  
Beiko DT(1998)Detailed diagnoses and procedures, National Hospital Discharge Survey, 1996 Vital Health Stat 13 i–iii 1-151
[10]  
Nickel JC(2001)Natural history of benign prostatic hyperplasia Urology 58 5-16